Watchdog Approved Diet Pills

Regulation For Over-The-Counter Diet Pills Video

10th June 2013

Video Transcript

The profits that can be made from diet pills can be massive, so it's understandable that lots of bodies want to get involved, but these can make things confusing – or even dangerous – for the people who are buying them.

In the US alone in 2013, the weight loss market will be worth around $66 billion, including cosmetic procedures and other treatments, while growing obesity levels across the world mean that the number of people jumping on the bandwagon could well grow.

This results in thousands of different products flooding the market and it can be difficult for the US, UK and European authorities to keep track of which ones work, which have no effects and which are downright dangerous to human life.

With this in mind, it seems a no-brainer that there should be greater regulation for over-the-counter diet pills, but the practicalities make it virtually impossible for every supplement to be tested and approved or rejected. In fact, some of the regulation that there is risks confusing matters for consumers.

Take the phrase 'clinically proven' – while one smaller trial could prove that an ingredient works, a larger one could show that it doesn't. However, a firm wanting to sell a diet pill featuring that ingredient could still say it had been clinically proven.

Then there are products called a 'certified medical device' – that's just a loophole so that it can be sold without conforming to food or drug regulation, so there could be anything in those kinds of capsules.

Until official regulation becomes infallible, you need to use commonsense before opting for a diet supplement, such as consulting your doctor or checking to see if a product has features on Diet Pills Watchdog. If it's not on here, submit a consumer report and find out the experiences of other users.

Read Less

Leave a Reply

Be nice. Keep it clean. Stay on topic. Please do not spam.

* Review comments: Please disclosure if you have any financial interest in the product.